Showing 1411-1420 of 8649 results for "".
- Valitor Presents Preclinical Safety Data on Long-Acting Anti-VEGF VLTR-559 for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-safety-data-on-long-acting-anti-vegf-vltr-559-for-wet-amd/2484137/Valitor announced new preclinical data on VLTR-559, its long-acting anti-VEGF biologic in development for wet age-related macular degeneration (AMD). The findings were featured in a presentation at the Ophthalmology Futures Retina Forum.
- Ashvattha Therapeutics Reports Positive Phase 2 Results for Potential First-in-Class Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-reports-positive-phase-2-results-for-potential-first-in-class-treatment-for-dme-and-wet-amd/2484136/Ashvattha Therapeutics announced positive topline results from its phase 2 study of migaldendranib (MGB) in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) at the Euretina Congress. MGB is
- AAVantgarde Bio Presents Clinical Data from LUCE-1 Gene Therapy Trial in Usher Syndrome Type 1Bhttps://modernod.com/news/aavantgarde-bio-presents-clinical-data-from-luce-1-gene-therapy-trial-in-usher-syndrome-type-1b/2484135/AAVantgarde Bio announced updated clinical results from its ongoing LUCE-1 phase 1/2 study of AAVB-081, presented at the 25th European Society of Retina Specialists (EURETINA) annual congress in Paris. The LUCE-1 study
- Roche Receives CE Mark for Contivue Port Delivery Platform with Susvimo in Wet AMDhttps://modernod.com/news/roche-receives-ce-mark-for-contivue-port-delivery-platform-with-susvimo-in-wet-amd/2484134/The European Union (EU) has granted CE mark for Roche's Port Delivery Platform containing Susvimo, which will be branded as Contivue in the EU. Contivue provides sustained ocular drug delivery for patients living with wet age-related macular
- PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025https://modernod.com/news/pulsesight-therapeutics-to-present-new-data-on-iron-dysregulation-and-ferroptosis-in-amd-at-euretina-2025/2484133/PulseSight Therapeutics announced that its Chief Scientific Officer, Thierry Bordet, PhD, will present new clinical and preclinical findings on the role of iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th Euretina Congre
- Contact Lens Institute Extends Partnership with Actress Kate Flannery for The EASY Way Campaignhttps://modernod.com/news/contact-lens-institute-extends-partnership-with-actress-kate-flannery-for-the-easy-way-campaign/2484132/The Contact Lens Institute (CLI) announced the continuation of its partnership with actress and comedian Kate Flannery to promote 'The EASY Way,' an initiative that aims to help eye care professionals encourage healthy contact lens wear-and-care b
- American Academy of Optometry Announces 2025 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2025-award-recipients/2484131/Each year, the American Academy of Optometry (AAOpt) recognizes distinguished individuals whose contributions advance the profession of optometry and vision science. The Academy’s awardees are nominated by fellows and are based on contributions made in t
- European Commission Approves Mynzepli as a Biosimilar to Eyleahttps://modernod.com/news/european-commission-approves-mynzepli-as-a-biosimilar-to-eylea/2484127/The European Commission has granted marketing authorization for Mynzepli (aflibercept), a biosimilar to Eylea, developed by Alvotech in partnership with Advanz Pharma. The centralized authorization applies t
- FDA Extends Target Action Dates to Fourth Quarter for Two Eylea HD Submissionshttps://modernod.com/news/fda-extends-target-action-dates-to-fourth-quarter-for-two-eylea-hd-submissions/2484126/Due to problems identified in a general FDA inspection of its third-party contract manufacturer, the FDA has extended the target action dates to the fourth quarter of 2025 for two Eylea HD (aflibercept injection 8 mg) regulatory submissions. The submissions include a prior-approval
- FDA Grants Fast Track Designation to Aldeyra’s ADX-2191 for Retinitis Pigmentosahttps://modernod.com/news/fda-grants-fast-track-designation-to-aldeyras-adx-2191-for-retinitis-pigmentosa/2484124/The FDA has granted Fast Track Designation for Aldeyra Therapeutics' ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa (RP). The FDA’s Fast Track progra